Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs
- PMID: 17532483
- PMCID: PMC2025703
- DOI: 10.1016/j.antiviral.2007.03.005
Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs
Abstract
Prodrugs of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD), organic salts of DAPD, 5'-L-valyl DAPD and N-1 substituted (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) have been synthesized with the objective of finding molecules which might be superior to DAPD and DXG in solubility as well as pharmacologic profiles. Synthesized prodrugs were evaluated for anti-HIV activity against HIV-1(LAI) in primary human lymphocytes (PBM cells) as well as their cytotoxicity in PBM, CEM and Vero cells. DAPD prodrugs, modified at the C6 position of the purine ring, demonstrated several folds of enhanced anti-HIV activity in comparison to the parent compound DAPD without increasing the toxicity. The presence of alkyl amino groups at the C6 position of the purine ring increased the antiviral potency several folds, and the most potent compound (-)-beta-D-(2R,4R)-1,3-dioxolane-2-amino-6-aminoethyl purine (8) was 17 times more potent than that of DAPD. 5'-L-Valyl DAPD 20 and organic acid salts 21-24 also exhibited enhanced anti-HIV activity in comparison to DAPD, while DXG prodrugs 16 and 17 exhibited lower potency than that of DXG or DAPD.
Figures



Similar articles
-
Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.Antimicrob Agents Chemother. 2001 Jan;45(1):158-65. doi: 10.1128/AAC.45.1.158-165.2001. Antimicrob Agents Chemother. 2001. PMID: 11120959 Free PMC article.
-
Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):11-20. doi: 10.1097/00042560-200201010-00002. J Acquir Immune Defic Syndr. 2002. PMID: 11782585
-
Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.Antimicrob Agents Chemother. 1999 Oct;43(10):2376-82. doi: 10.1128/AAC.43.10.2376. Antimicrob Agents Chemother. 1999. PMID: 10508010 Free PMC article.
-
[Advances in the study of nucleoside antiviral drugs].Yao Xue Xue Bao. 2006 Aug;41(8):689-93. Yao Xue Xue Bao. 2006. PMID: 17039770 Review. Chinese. No abstract available.
-
Anti-HIV Nucleoside Phosphonate GS-9148 and Its Prodrug GS-9131: Scale Up of a 2'-F Modified Cyclic Nucleoside Phosphonate and Synthesis of Selected Amidate Prodrugs.Curr Protoc Nucleic Acid Chem. 2014 Mar 26;56:14.10.1-21. doi: 10.1002/0471142700.nc1410s56. Curr Protoc Nucleic Acid Chem. 2014. PMID: 25606977 Review.
Cited by
-
Scaleable processes for the synthesis of (-)-β-D-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (-)-β-D-2-aminopurine dioxolane (APD).Tetrahedron. 2012 Jul 22;68(29):5738-5743. doi: 10.1016/j.tet.2012.05.039. Epub 2012 May 16. Tetrahedron. 2012. PMID: 23162170 Free PMC article.
-
Crystal structure of 5''-(4-chloro-benzyl-idene)-4'-(4-chloro-phen-yl)-1'-methyltri-spiro[acenapthylene-1,2'-pyrrolidine-3',1''-cyclo-hexane-3'',2'''-[1,3]dioxane]-2(1H),6''-dione.Acta Crystallogr E Crystallogr Commun. 2015 Oct 3;71(Pt 11):o814-5. doi: 10.1107/S2056989015018034. eCollection 2015 Nov 1. Acta Crystallogr E Crystallogr Commun. 2015. PMID: 26594541 Free PMC article.
-
Biosynthesis of anti-HCV compounds using thermophilic microorganisms.Bioorg Med Chem Lett. 2012 Oct 1;22(19):6059-62. doi: 10.1016/j.bmcl.2012.08.045. Epub 2012 Aug 21. Bioorg Med Chem Lett. 2012. PMID: 22959520 Free PMC article.
References
-
- Badet B, Julia M, Lefebvre C. The efficiency of diphenylsulfonium salts as alkylating agents. Bull. Soc. Chim. Fr. 1984;11:431–434.
-
- Baer HP, Drummond GI, Gillis J. Studies on the specificity and mechanism of action of adenosine deaminase. Arch. Biochem. Biophys. 1968;123:172–178. - PubMed
-
- Balzarini J. Metabolism and mechanism of antiviral action of purine and pyrimidine derivatives. Pharm. World Sci. 1994;16:113–126. - PubMed
-
- Barchi JJ, Marquez VE, Driscoll JS, Ford H, Mitsuya H, Shirasaka T, Aoki S, Kelley JA. Potential anti-AIDS drugs. lipophilic, adenosine deaminase-activated prodrugs. J. Med. Chem. 1991;34:1647–1655. - PubMed
-
- Bazmi HZ, Hammond JL, Cavalcanti SCH, Chu CK, Schinazi RF, Mellors JW. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 2000;44:1783–1788. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical